Company profile for Tubulis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for p...
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Butenandtstraße 1, 81375 München
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

PEGS Boston Summit

PEGS Boston Summit

Not Confirmed

envelop Contact Supplier

PEGS Boston Summit

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/asco-tubulis-touts-ovarian-cancer-data-attracted-gilead-buyout-deal-closes

FIERCE BIOTECH
30 May 2026

https://www.pharmiweb.com/press-release/2026-05-21/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio

PHARMIWEB
22 May 2026

https://www.businesswire.com/news/home/20260421709537/en/Tubulis-to-Present-Phase-IIIa-Trial-Data-for-ADC-Candidate-TUB-040-in-Platinum-resistant-Ovarian-Cancer-in-Rapid-Oral-Presentation-at-ASCO-2026

BUSINESSWIRE
21 Apr 2026

https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline

PRESS RELEASE
07 Apr 2026

https://www.businesswire.com/news/home/20260127919942/en/Tubulis-Adds-Steve-Kelsey-as-Independent-Director-to-its-Advisory-Board

BUSINESSWIRE
27 Jan 2026

https://www.businesswire.com/news/home/20260121668600/en/Tubulis-Unveils-Alco5-Conjugation-Platforms-Ability-to-Expand-ADC-Payload-Scope-in-Nature-Communications

BUSINESSWIRE
21 Jan 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty